{"ticker": {"uuid": "e9d804f2-78dd-4947-b0ed-9f6fa5d1be63", "symbol": "DRMA", "name": "Dermata Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to earnings forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMAW", "summary": "This article provides the \"Price to earnings forward\" data for Dermata Therapeutics, Inc. (NASDAQ:DRMAW). It indicates that the market is currently closed, with no trades, and the data is sourced from ICE Data Services and FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T06:40:01", "published_display": "19 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMAW", "summary": "The article briefly mentions the price to sales forward for Dermata Therapeutics, Inc. (NASDAQ: DRMAW). It is a financial data point presented on the TradingView platform, with no further details or analysis provided within the content itself. The majority of the content consists", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T21:41:24", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings", "summary": "This article provides access to Dermata Therapeutics, Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports from 2021 through 2026. Key updates mentioned include strategic pivots to DTC skincare, clinical trial results for DMT310, and o", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/documents/", "source_name": "TradingView", "published_at": "2026-07-04T12:40:49", "published_display": "04 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dermata Therapeutics, Inc. \u2013 BOATS:DRMAW", "summary": "This article provides financial information for Dermata Therapeutics, Inc. (DRMAW) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the \"Price to earnings forward\" metric for the company. The content primarily lists navigation and dat", "url": "https://www.tradingview.com/symbols/BOATS-DRMAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:09:22", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Dermata Therapeutics, Inc. (DRMA) stock for 2027, according to one analyst. It details the current stock price, market capitalization, volatility, and historical performance, alongside information on earnings, revenue, and emp", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T15:09:41", "published_display": "28 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMA", "summary": "This article provides the \"Price to sales forward\" value for Dermata Therapeutics, Inc. (NASDAQ: DRMA). It appears to be a financial data snippet from a larger platform, possibly TradingView, indicating a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:31", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics, Inc. Actuals & Estimates (NASDAQ:DRMA)", "summary": "This article provides an overview of Dermata Therapeutics, Inc. (NASDAQ:DRMA) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, ", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:31", "published_display": "26 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMA", "summary": "The article provides a title indicating an analysis of Dermata Therapeutics, Inc.'s enterprise value to EBIT forward. It appears to be a stub or a placeholder page on TradingView, given the lack of actual financial data or detailed content beyond the heading and navigation elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:05", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Dermata Therapeutics Inc (DRMA), detailing its current stock price, market capitalization, and various technical indicators. It outlines support and resistance levels, indicator values like MACD, RSI, and moving averages, all of which", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/technical", "source_name": "TradingKey", "published_at": "2026-06-24T19:12:18", "published_display": "24 Jun 2026 19:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Dermata Therapeutics Inc (DRMAW), covering its support and resistance levels, various technical indicators like MACD and RSI, and moving averages. The analysis indicates a \"Sell\" signal based on moving averages and a mix of buy and se", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/technical", "source_name": "TradingKey", "published_at": "2026-06-23T21:09:08", "published_display": "23 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Dermata Therapeutics Inc (DRMA), highlighting that one analyst rates the stock as \"Buy\" with a target price of $10.00, representing a 200.75% upside. The company's previous quarter's EPS was -$1.65, significantly below the market exp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:29", "published_display": "19 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Institutional Confidence", "summary": "This article provides an overview of Dermata Therapeutics Inc (DRMA)'s institutional confidence, detailing changes in institutional shareholdings. Key shareholders include Proehl (Gerald T), Intracoastal Capital, L.L.C., and Van Hoose (Kyri K), with notable increases in holdings ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T15:40:05", "published_display": "18 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief valuation analysis for Dermata Therapeutics Inc (DRMA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The current stock price and market capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:05", "published_display": "18 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Institutional Confidence", "summary": "The article provides an overview of Dermata Therapeutics Inc (DRMAW) with a focus on its institutional confidence", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:05", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Dermata Therapeutics Inc (DRMA), listing major individual and institutional holders and their respective proportions. It also presents a historical overview of institutional shareholding data from Q1 2023 to Q1 2026, showing chang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:00", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Dermata Therapeutics Inc.'s (DRMA) dividend history and stock split events. It states that the company has not distributed any dividends over the past five years. The article also lists several stock split events, all described as \"Merger\" typ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:00", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc", "summary": "This article for Dermata Therapeutics Inc (DRMAW) on TradingKey.com indicates that relevant revenue breakdown data for business segments and regional contributions have not yet been disclosed by the company. It provides basic stock information such as the current price and market", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:09:25", "published_display": "17 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Dermata Therapeutics Inc (DRMAW)'s dividend and stock split history, indicating that the company has distributed $0.00 in dividends over the past five years and has no recorded stock splits. It presents current stock performance data, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-16T22:09:25", "published_display": "16 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale", "summary": "Dermata Therapeutics (NASDAQ: DRMA) director Kathleen D. Scott reported a small open-market sale of 11 shares of common stock at $1.1901 per share. Following this transaction, she holds no direct shares but maintains indirect ownership of 1 share through the Scott 2008 Trust. The", "url": "https://www.stocktitan.net/sec-filings/DRMA/form-4-dermata-therapeutics-inc-insider-trading-activity-2d52b4c3d2ec.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:09:25", "published_display": "16 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOY0tTQ1ZjTXFNU2JRNm9BOS1nb256OENscEU0SnozVUZVRkxzRnRhVVFuR3hRNjRDZXFzQkpIampHT3NYVl9UUVp1UVJsZEFnQVB5LW9qTThlM2Zuc2ZqUFFhWmc2V2Nrd1U3dlppRHVPSnRuUGZObVU4ZW40cmpReEFjS0E?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOclRoQU5CWlZ6LUwwWkFyZENydUlqXzJ5Vk9LSlNCZWd1VWs2Vlh5WUFHVGxnanZ2WVhhdlRwN2xxOHJoR0o5TlJCd09UQWd2aWV6VkxEQzQ3Zl9PUC0wSHpwM0FqdmZwaUt2WHVEc0c0LTFzMUNGUW03Z0FvcElmeXlqM1Q?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA - Dermata Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and company information for Dermata Therapeutics Inc. (DRMA), including its latest closing price, financial metrics, insider ownership, and recent corporate news. It highlights various financial figures such as market capitalization, i", "url": "https://finviz.com/stock?t=DRMA", "source_name": "Finviz", "published_at": "2026-06-02T23:40:56", "published_display": "02 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D", "summary": "Dermata Therapeutics, Inc.'s CFO, Kyri Van Hoose, has reported a 9% beneficial ownership stake in the company, totaling 384,352 shares. This significant holding, which includes common shares, warrants, and stock options, largely stems from a private placement in December 2025 whe", "url": "https://www.stocktitan.net/sec-filings/DRMA/schedule-13d-dermata-therapeutics-inc-major-shareholder-acquisition-5-5d6b06b0df10.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:37", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Dermata Therapeutics, Inc. SEC Filing", "summary": "Dermata Therapeutics, Inc. (DRMA) has had an SEC filing of form EFFECT, signaling that a previous S-3 shelf registration statement has become effective. The filing states an effectiveness date of May 29, 2026, and provides details about the company's CIK and file number. The arti", "url": "https://www.stocktitan.net/sec-filings/DRMA/effect-dermata-therapeutics-inc-sec-filing-7d1f593986c6.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:37", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Dermata Therapeutics, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. It allows users to explore the company's financial performance and operational updates, dating back to 2021, to aid in making informed decisio", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/documents/", "source_name": "TradingView", "published_at": "2026-05-31T08:49:20", "published_display": "31 May 2026 08:49", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration", "summary": "Dermata Therapeutics (NASDAQ: DRMA) has filed a $100 million shelf registration for a variety of securities, including common stock, preferred stock, warrants, and debt securities. This filing provides the company with flexibility to raise capital as needed, with specific terms f", "url": "https://www.stocktitan.net/sec-filings/DRMA/424b3-dermata-therapeutics-inc-prospectus-filed-pursuant-to-rule-424--2ae41734ef47.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:09:36", "published_display": "29 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan \u2013 Form 8-K Filing Summary", "summary": "Dermata Therapeutics, Inc. filed an 8-K detailing outcomes from its Annual Meeting, notably approving an increase in shares for its 2021 Omnibus Equity Incentive Plan from 153,586 to 402,214, alongside warrant repricing. These approvals, impacting potential dilution and employee ", "url": "https://www.minichart.com.sg/2026/05/28/dermata-therapeutics-adopts-fourth-amendment-to-2021-omnibus-equity-incentive-plan-form-8-k-filing-summary/", "source_name": "Minichart", "published_at": "2026-05-28T08:39:05", "published_display": "28 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes", "summary": "Dermata Therapeutics, Inc. (NASDAQ: DRMA) stockholders approved all management proposals at their 2026 annual meeting, including expanding the 2021 Omnibus Equity Incentive Plan to 402,214 shares and approving warrant-related issuances and repricing. These approvals provide the c", "url": "https://www.stocktitan.net/sec-filings/DRMA/8-k-dermata-therapeutics-inc-reports-material-event-aec065ce8fc7.html", "source_name": "Stock Titan", "published_at": "2026-05-27T21:11:04", "published_display": "27 May 2026 21:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (Nasdaq:DRMA) - Stock Analysis", "summary": "This analysis of Dermata Therapeutics (Nasdaq:DRMA) highlights its current market cap of US$5.2m and a highly undervalued analyst price target of US$4.00, despite significant past share price declines. The company faces major risks including having less than a year of cash runway", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-drma/dermata-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-05-26T20:40:30", "published_display": "26 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants", "summary": "Dermata Therapeutics (NASDAQ: DRMA) has filed a shelf registration statement (S-3/A) to sell up to $100 million in various securities, including common stock, preferred stock, warrants, and debt securities. This filing indicates the company's strategic shift from Rx dermatology t", "url": "https://www.stocktitan.net/sec-filings/DRMA/s-3-a-dermata-therapeutics-inc-amended-shelf-registration-statement-3394ca8b7098.html", "source_name": "Stock Titan", "published_at": "2026-05-22T21:10:00", "published_display": "22 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026", "summary": "", "url": "https://finance.yahoo.com/news/dermata-therapeutics-provides-corporate-reports-200500093.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-13T20:05:00+00:00", "published_display": "13 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Once-weekly Tome mask aims to bring professional skincare home by mid-2026", "summary": "Dermata Therapeutics is pivoting to a direct-to-consumer skincare model with its new Tome brand, aiming to launch its first product, a once-weekly Foundational Treatment mask, in mid-2026. The company reported $6.9 million in cash and cash equivalents as of Q1 2026, with funding ", "url": "https://www.stocktitan.net/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-kiq2xydvz3g6.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:38:50", "published_display": "13 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dermata Therapeutics Ramps Up Skincare Division with New VP Appointment\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPSEI3LW1hVFNOc09UVDVNQ1JJTGNDQUc1cEVubGxidUZEZnRhREwzZnpjNC1xVEtRTmE1UlpiZ2FIQUtqajl5Y3FfMkFabjJJUlR5YnpLWGpPSWpXN01GYVpiT3dpS3Z1ZUNYam94YjZwSU1fbE9LQVlaOTRuUllSdlhpTQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata\u2019s Strategic Pivot: New Skincare Line on the Horizon", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOUVdmQlh5M2JxNHNneDZhZVloVVFobC1sdUNieXdzN2NoQ2prWFJ1VTd4eFBPYmZKYnNaVFBzVGdYWlZBS0pOM3lXbWpVUDJRMHk3WndUTnZZVEh2NE9qeHRXeV9zVkw3MTN0RWFnaUZfM0dNOE4yZmFjNHFnWndqdG9vOXdOUUE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skincare firm Dermata raises $4.1M to back new over-the-counter acne kit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUWV0Nm9jcFZOTi0zR0xYVDV4Uk9GSXJ0N2RBeExIeTBFbDk0N24teVItWnRQVjNuZEx3clNPSi15dktEcmZURGd6X0JwdHk1RE1yVXptTVE1TUg1MzI2N2ZUMG1NS0NsbkpVSDgxTEI0LVhtVVI4Q2pCSWhLNHdoLTZ0R1BJMXdfUWx3SUV2bEZjU3ptWC1sbkFHQXpNX3J4X01mXzFyV09NWnJ5OUJQWlBXUzhLNEVaRm5GeGR6TWQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSXJGUVltLUZGeEtqc3ZZdDIycWlPT2JXbVVmZWVha1FxellDLUNIY3FaRDdDTnM4ZE55eFNnTlpGdjdxQXhycl9uYnBaYzRULUFnMklvVUVZU2taYk9ROC1iZXNCVVdLWmJHbzhDcmQ5a1Y1Vm05aE5mVGtUcGV3NVh2aFB4MXZOVzdSRlZzTXNPYW9oVFVrcGhDZ3V2QkJYbGNHVFB6aDFYZ3Z5Nk11X3RGc2ItbFJfcFBUalRB?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (DRMA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2eTNvOTR1VU5uZFgzdzl0aWZsWmZnWW9sa3VPMHBGUW1jSmwtWWlVVTVZLVNYTXBUenBqVWltRzNpRkQ1aUE4eVRkaENEYktCRF9N?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:04:37+00:00", "published_display": "25 Apr 2025 03:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silexion Therapeutics (SLXN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1PNU1fQjV0dW5zYWl0ZDFwLTIxYXlEUEhQTC12NHBaZ1h0dGZXaWZXT3k0ek1QN0dXa1NqdXVjRVl6V21VVTd0U3gzN0hTQkpCRVZZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:34:06+00:00", "published_display": "24 Apr 2025 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA Stock Price and Chart \u2014 NASDAQ:DRMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE42NDFsSVdQeHphUmZJR09kQ0ZTb1l3ajJYVXdNbEV2TDhiU0JfaWFNazk1MWRtX1pJcmNsLVQyWU9mZU9qeDBPblNiSDFILVhlVmNvQVBjZTBrZERT?oc=5", "source_name": "TradingView", "published_at": "2023-04-18T07:00:00+00:00", "published_display": "18 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMAW", "summary": "This article provides the \"Price to earnings forward\" data for Dermata Therapeutics, Inc. (NASDAQ:DRMAW). It indicates that the market is currently closed, with no trades, and the data is sourced from ICE Data Services and FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T06:40:01", "published_display": "19 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMAW", "summary": "The article briefly mentions the price to sales forward for Dermata Therapeutics, Inc. (NASDAQ: DRMAW). It is a financial data point presented on the TradingView platform, with no further details or analysis provided within the content itself. The majority of the content consists", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T21:41:24", "published_display": "13 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings", "summary": "This article provides access to Dermata Therapeutics, Inc.'s SEC filings and other financial documents, including quarterly and annual earnings reports from 2021 through 2026. Key updates mentioned include strategic pivots to DTC skincare, clinical trial results for DMT310, and o", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMAW/documents/", "source_name": "TradingView", "published_at": "2026-07-04T12:40:49", "published_display": "04 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dermata Therapeutics, Inc. \u2013 BOATS:DRMAW", "summary": "This article provides financial information for Dermata Therapeutics, Inc. (DRMAW) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the \"Price to earnings forward\" metric for the company. The content primarily lists navigation and dat", "url": "https://www.tradingview.com/symbols/BOATS-DRMAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:09:22", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Dermata Therapeutics, Inc. (DRMA) stock for 2027, according to one analyst. It details the current stock price, market capitalization, volatility, and historical performance, alongside information on earnings, revenue, and emp", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T15:09:41", "published_display": "28 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMA", "summary": "This article provides the \"Price to sales forward\" value for Dermata Therapeutics, Inc. (NASDAQ: DRMA). It appears to be a financial data snippet from a larger platform, possibly TradingView, indicating a specific financial metric for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:31", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics, Inc. Actuals & Estimates (NASDAQ:DRMA)", "summary": "This article provides an overview of Dermata Therapeutics, Inc. (NASDAQ:DRMA) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, ", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:31", "published_display": "26 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMA", "summary": "The article provides a title indicating an analysis of Dermata Therapeutics, Inc.'s enterprise value to EBIT forward. It appears to be a stub or a placeholder page on TradingView, given the lack of actual financial data or detailed content beyond the heading and navigation elemen", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:05", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Dermata Therapeutics Inc (DRMA), detailing its current stock price, market capitalization, and various technical indicators. It outlines support and resistance levels, indicator values like MACD, RSI, and moving averages, all of which", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/technical", "source_name": "TradingKey", "published_at": "2026-06-24T19:12:18", "published_display": "24 Jun 2026 19:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Dermata Therapeutics Inc (DRMAW), covering its support and resistance levels, various technical indicators like MACD and RSI, and moving averages. The analysis indicates a \"Sell\" signal based on moving averages and a mix of buy and se", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/technical", "source_name": "TradingKey", "published_at": "2026-06-23T21:09:08", "published_display": "23 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Dermata Therapeutics Inc (DRMA), highlighting that one analyst rates the stock as \"Buy\" with a target price of $10.00, representing a 200.75% upside. The company's previous quarter's EPS was -$1.65, significantly below the market exp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:10:29", "published_display": "19 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Institutional Confidence", "summary": "This article provides an overview of Dermata Therapeutics Inc (DRMA)'s institutional confidence, detailing changes in institutional shareholdings. Key shareholders include Proehl (Gerald T), Intracoastal Capital, L.L.C., and Van Hoose (Kyri K), with notable increases in holdings ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T15:40:05", "published_display": "18 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief valuation analysis for Dermata Therapeutics Inc (DRMA), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The current stock price and market capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:05", "published_display": "18 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Institutional Confidence", "summary": "The article provides an overview of Dermata Therapeutics Inc (DRMAW) with a focus on its institutional confidence", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:05", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Dermata Therapeutics Inc (DRMA), listing major individual and institutional holders and their respective proportions. It also presents a historical overview of institutional shareholding data from Q1 2023 to Q1 2026, showing chang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:00", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Dermata Therapeutics Inc.'s (DRMA) dividend history and stock split events. It states that the company has not distributed any dividends over the past five years. The article also lists several stock split events, all described as \"Merger\" typ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drma/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:00", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc", "summary": "This article for Dermata Therapeutics Inc (DRMAW) on TradingKey.com indicates that relevant revenue breakdown data for business segments and regional contributions have not yet been disclosed by the company. It provides basic stock information such as the current price and market", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:09:25", "published_display": "17 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Dermata Therapeutics Inc (DRMAW)'s dividend and stock split history, indicating that the company has distributed $0.00 in dividends over the past five years and has no recorded stock splits. It presents current stock performance data, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drmaw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-16T22:09:25", "published_display": "16 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale", "summary": "Dermata Therapeutics (NASDAQ: DRMA) director Kathleen D. Scott reported a small open-market sale of 11 shares of common stock at $1.1901 per share. Following this transaction, she holds no direct shares but maintains indirect ownership of 1 share through the Scott 2008 Trust. The", "url": "https://www.stocktitan.net/sec-filings/DRMA/form-4-dermata-therapeutics-inc-insider-trading-activity-2d52b4c3d2ec.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:09:25", "published_display": "16 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOY0tTQ1ZjTXFNU2JRNm9BOS1nb256OENscEU0SnozVUZVRkxzRnRhVVFuR3hRNjRDZXFzQkpIampHT3NYVl9UUVp1UVJsZEFnQVB5LW9qTThlM2Zuc2ZqUFFhWmc2V2Nrd1U3dlppRHVPSnRuUGZObVU4ZW40cmpReEFjS0E?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOclRoQU5CWlZ6LUwwWkFyZENydUlqXzJ5Vk9LSlNCZWd1VWs2Vlh5WUFHVGxnanZ2WVhhdlRwN2xxOHJoR0o5TlJCd09UQWd2aWV6VkxEQzQ3Zl9PUC0wSHpwM0FqdmZwaUt2WHVEc0c0LTFzMUNGUW03Z0FvcElmeXlqM1Q?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA - Dermata Therapeutics Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and company information for Dermata Therapeutics Inc. (DRMA), including its latest closing price, financial metrics, insider ownership, and recent corporate news. It highlights various financial figures such as market capitalization, i", "url": "https://finviz.com/stock?t=DRMA", "source_name": "Finviz", "published_at": "2026-06-02T23:40:56", "published_display": "02 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D", "summary": "Dermata Therapeutics, Inc.'s CFO, Kyri Van Hoose, has reported a 9% beneficial ownership stake in the company, totaling 384,352 shares. This significant holding, which includes common shares, warrants, and stock options, largely stems from a private placement in December 2025 whe", "url": "https://www.stocktitan.net/sec-filings/DRMA/schedule-13d-dermata-therapeutics-inc-major-shareholder-acquisition-5-5d6b06b0df10.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:37", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Dermata Therapeutics, Inc. SEC Filing", "summary": "Dermata Therapeutics, Inc. (DRMA) has had an SEC filing of form EFFECT, signaling that a previous S-3 shelf registration statement has become effective. The filing states an effectiveness date of May 29, 2026, and provides details about the company's CIK and file number. The arti", "url": "https://www.stocktitan.net/sec-filings/DRMA/effect-dermata-therapeutics-inc-sec-filing-7d1f593986c6.html", "source_name": "Stock Titan", "published_at": "2026-06-01T10:39:37", "published_display": "01 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Dermata Therapeutics, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. It allows users to explore the company's financial performance and operational updates, dating back to 2021, to aid in making informed decisio", "url": "https://www.tradingview.com/symbols/NASDAQ-DRMA/documents/", "source_name": "TradingView", "published_at": "2026-05-31T08:49:20", "published_display": "31 May 2026 08:49", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration", "summary": "Dermata Therapeutics (NASDAQ: DRMA) has filed a $100 million shelf registration for a variety of securities, including common stock, preferred stock, warrants, and debt securities. This filing provides the company with flexibility to raise capital as needed, with specific terms f", "url": "https://www.stocktitan.net/sec-filings/DRMA/424b3-dermata-therapeutics-inc-prospectus-filed-pursuant-to-rule-424--2ae41734ef47.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:09:36", "published_display": "29 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan \u2013 Form 8-K Filing Summary", "summary": "Dermata Therapeutics, Inc. filed an 8-K detailing outcomes from its Annual Meeting, notably approving an increase in shares for its 2021 Omnibus Equity Incentive Plan from 153,586 to 402,214, alongside warrant repricing. These approvals, impacting potential dilution and employee ", "url": "https://www.minichart.com.sg/2026/05/28/dermata-therapeutics-adopts-fourth-amendment-to-2021-omnibus-equity-incentive-plan-form-8-k-filing-summary/", "source_name": "Minichart", "published_at": "2026-05-28T08:39:05", "published_display": "28 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes", "summary": "Dermata Therapeutics, Inc. (NASDAQ: DRMA) stockholders approved all management proposals at their 2026 annual meeting, including expanding the 2021 Omnibus Equity Incentive Plan to 402,214 shares and approving warrant-related issuances and repricing. These approvals provide the c", "url": "https://www.stocktitan.net/sec-filings/DRMA/8-k-dermata-therapeutics-inc-reports-material-event-aec065ce8fc7.html", "source_name": "Stock Titan", "published_at": "2026-05-27T21:11:04", "published_display": "27 May 2026 21:11", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (Nasdaq:DRMA) - Stock Analysis", "summary": "This analysis of Dermata Therapeutics (Nasdaq:DRMA) highlights its current market cap of US$5.2m and a highly undervalued analyst price target of US$4.00, despite significant past share price declines. The company faces major risks including having less than a year of cash runway", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-drma/dermata-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-05-26T20:40:30", "published_display": "26 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants", "summary": "Dermata Therapeutics (NASDAQ: DRMA) has filed a shelf registration statement (S-3/A) to sell up to $100 million in various securities, including common stock, preferred stock, warrants, and debt securities. This filing indicates the company's strategic shift from Rx dermatology t", "url": "https://www.stocktitan.net/sec-filings/DRMA/s-3-a-dermata-therapeutics-inc-amended-shelf-registration-statement-3394ca8b7098.html", "source_name": "Stock Titan", "published_at": "2026-05-22T21:10:00", "published_display": "22 May 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026", "summary": "", "url": "https://finance.yahoo.com/news/dermata-therapeutics-provides-corporate-reports-200500093.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-13T20:05:00+00:00", "published_display": "13 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Once-weekly Tome mask aims to bring professional skincare home by mid-2026", "summary": "Dermata Therapeutics is pivoting to a direct-to-consumer skincare model with its new Tome brand, aiming to launch its first product, a once-weekly Foundational Treatment mask, in mid-2026. The company reported $6.9 million in cash and cash equivalents as of Q1 2026, with funding ", "url": "https://www.stocktitan.net/news/DRMA/dermata-therapeutics-provides-corporate-update-and-reports-financial-kiq2xydvz3g6.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:38:50", "published_display": "13 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics Ramps Up Skincare Division with New VP Appointment\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPSEI3LW1hVFNOc09UVDVNQ1JJTGNDQUc1cEVubGxidUZEZnRhREwzZnpjNC1xVEtRTmE1UlpiZ2FIQUtqajl5Y3FfMkFabjJJUlR5YnpLWGpPSWpXN01GYVpiT3dpS3Z1ZUNYam94YjZwSU1fbE9LQVlaOTRuUllSdlhpTQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata\u2019s Strategic Pivot: New Skincare Line on the Horizon", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOUVdmQlh5M2JxNHNneDZhZVloVVFobC1sdUNieXdzN2NoQ2prWFJ1VTd4eFBPYmZKYnNaVFBzVGdYWlZBS0pOM3lXbWpVUDJRMHk3WndUTnZZVEh2NE9qeHRXeV9zVkw3MTN0RWFnaUZfM0dNOE4yZmFjNHFnWndqdG9vOXdOUUE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skincare firm Dermata raises $4.1M to back new over-the-counter acne kit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUWV0Nm9jcFZOTi0zR0xYVDV4Uk9GSXJ0N2RBeExIeTBFbDk0N24teVItWnRQVjNuZEx3clNPSi15dktEcmZURGd6X0JwdHk1RE1yVXptTVE1TUg1MzI2N2ZUMG1NS0NsbkpVSDgxTEI0LVhtVVI4Q2pCSWhLNHdoLTZ0R1BJMXdfUWx3SUV2bEZjU3ptWC1sbkFHQXpNX3J4X01mXzFyV09NWnJ5OUJQWlBXUzhLNEVaRm5GeGR6TWQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSXJGUVltLUZGeEtqc3ZZdDIycWlPT2JXbVVmZWVha1FxellDLUNIY3FaRDdDTnM4ZE55eFNnTlpGdjdxQXhycl9uYnBaYzRULUFnMklvVUVZU2taYk9ROC1iZXNCVVdLWmJHbzhDcmQ5a1Y1Vm05aE5mVGtUcGV3NVh2aFB4MXZOVzdSRlZzTXNPYW9oVFVrcGhDZ3V2QkJYbGNHVFB6aDFYZ3Z5Nk11X3RGc2ItbFJfcFBUalRB?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermata Therapeutics (DRMA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2eTNvOTR1VU5uZFgzdzl0aWZsWmZnWW9sa3VPMHBGUW1jSmwtWWlVVTVZLVNYTXBUenBqVWltRzNpRkQ1aUE4eVRkaENEYktCRF9N?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:04:37+00:00", "published_display": "25 Apr 2025 03:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Silexion Therapeutics (SLXN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1PNU1fQjV0dW5zYWl0ZDFwLTIxYXlEUEhQTC12NHBaZ1h0dGZXaWZXT3k0ek1QN0dXa1NqdXVjRVl6V21VVTd0U3gzN0hTQkpCRVZZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:34:06+00:00", "published_display": "24 Apr 2025 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRMA Stock Price and Chart \u2014 NASDAQ:DRMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE42NDFsSVdQeHphUmZJR09kQ0ZTb1l3ajJYVXdNbEV2TDhiU0JfaWFNazk1MWRtX1pJcmNsLVQyWU9mZU9qeDBPblNiSDFILVhlVmNvQVBjZTBrZERT?oc=5", "source_name": "TradingView", "published_at": "2023-04-18T07:00:00+00:00", "published_display": "18 Apr 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 48, "sentiment_summary": {"positive": 8, "negative": 7, "neutral": 33, "score": 50, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 1.33, "latest_week": "2026-07-17", "one_week_move": -0.7, "four_week_move": 13.7, "twelve_week_move": 7.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 2.344849, "market_dynamics_buy_signal": false, "relative_strength": -57.750197, "fair_value_gap": -96.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.2578, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.7% over one week, +13.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "TradingKey", "count": 10}, {"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 6}, {"label": "timothysykes.com", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Finviz", "count": 1}, {"label": "Minichart", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 17}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.7% over one week, +13.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Dermata Therapeutics, Inc. \u2013 NASDAQ:DRMAW"}], "updated_at": "2026-07-22T13:37:06.148755+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}